会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Delivery system for omeprazole and its salts
    • 奥美拉唑及其盐的输送系统
    • US06749867B2
    • 2004-06-15
    • US09991059
    • 2001-11-21
    • Joseph R. RobinsonJames W. McGinity
    • Joseph R. RobinsonJames W. McGinity
    • A61K914
    • A61K31/4439A61K9/2009A61K9/2054A61K9/282A61K9/2846A61K9/2866
    • The present invention provides a time-release dosage form for delivering an acid-labile pharmaceutical, such as omeprazole, into the upper portion of the gastrointestinal tract downstream of the stomach. The dosage form includes a drug-containing core surrounded by an inert time-release coating that delays release of the drug from the core until expiration of a certain time period after administration, generally 0.5-5.0 hours or 1-3 hours. When the gastrointestinal fluid contacts the core, the drug is released rapidly into the GI tract. The dosage form does not contain an enteric coating. The dosage form can also include one or more additional coatings exterior to the time-release coating to provide delivery of an immediately released loading dose of the acid-labile drug or another drug.
    • 本发明提供了用于将酸不稳定药物(例如奥美拉唑)输送到胃下游胃肠道上部的时间释放剂型。 剂型包括由惰性时间释放涂层包围的药物核心,其延迟药物从核心释放直到给药后一定时间段通常为0.5-5.0小时或1-3小时。 当胃肠液接触核心时,药物迅速释放到胃肠道。 剂型不含肠溶衣。 剂型还可以包括一个或多个在时间释放涂层外部的附加涂层,以提供立即释放的负载剂量的酸不稳定药物或另一种药物的递送。
    • 9. 发明授权
    • Ophthalmic suspensions
    • 眼科悬浮液
    • US5192535A
    • 1993-03-09
    • US544518
    • 1990-06-27
    • Jeffrey P. DavisSantosh K. ChandrasekaranYansheng SuRoy D. ArchibaldJoseph R. Robinson
    • Jeffrey P. DavisSantosh K. ChandrasekaranYansheng SuRoy D. ArchibaldJoseph R. Robinson
    • A61K9/107A61F2/14A61K9/00A61K9/64A61K9/70A61K31/765A61K47/32
    • A61K9/0048Y10S514/912Y10S514/913Y10S514/914Y10S514/915Y10S514/944Y10S514/953Y10S514/954
    • Lightly crosslinked polymers, preferably ones prepared by suspension or emulsion polymerizing at least about 90% by weight of a carboxyl-containing monoethylenically unsaturated monomer such as acrylic acid with from about 0.1% to about 5% by weight of a polyfunctional, and preferably difunctional, crosslinking agent such as divinyl glycol (3,4-dihydroxy-1,5-hexadiene), having a particle size of not more than about 50 .mu.m in equivalent spherical diameter, when formulated with an ophthalmic medicament, e.g., fluorometholone, into suspensions in aqueous medium in which the amount of polymer ranges from about 0.1% to about 6.5% by weight, based on the total weight of the aqueous suspension, the pH is from about 3.0 to about 6.5, and the osmotic pressure (osmolality or tonicity) is from about 10 mOsM to about 400 mOsM, provide new topical ophthalmic medicament delivery systems having suitably low viscosities which permit them to be easily administered to the eye in drop form, and hence be comfortably administrable in consistent, accurate dosages. These suspension will rapidly gel in the eye after coming into contact with the eye's tear fluid to a substantially greater viscosity than that of the originally-introduced suspension and thus remain in place for prolonged periods of time to provide sustained release of the ophthalmic medicament.
    • 轻度交联的聚合物,优选通过悬浮或乳液聚合至少约90重量%的含羧基的单烯属不饱和单体如丙烯酸与约0.1重量%至约5重量%的多官能,优选双官能的, 当与眼科药物(例如氟米龙)一起配制成悬浮液时,具有当量球形直径不大于约50μm的粒度的二乙烯基二醇(3,4-二羟基-1,5-己二烯)等交联剂 在水性介质中,其中聚合物的量为约0.1%至约6.5%(重量),基于水性悬浮液的总重量,pH为约3.0至约6.5,渗透压(渗透压或渗透压) 提供了约10mOsM至约400mOsM的新型局部眼科药物递送系统,其具有适当的低粘度,使得它们能够以滴剂形式容易地施用于眼睛,因此是 以一致,准确的剂量舒适地管理。 在与眼睛的泪液接触之后,这些悬浮液将在眼睛中快速凝胶至比最初引入的悬浮液的粘度显着更大的粘度,并因此保持在适当位置以延长时间以提供眼药物的持续释放。